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Abstract The role of endogenous animal opioids in the
biology of cancer is widely recognized but poorly under-
stood. This is, among others, because of the short half-life
of these peptides, which are quickly inactivated by endo-
peptidases, e.g., neutral endopeptidase (NEP, CD10). It has
been established that NEP is engaged in the modulation of
the tumor microenvironment, among others that of colon
cancer, by exerting influence on cell growth factors, the
extracellular matrix and other biologically active sub-
stances. Although there are some discrepancies among the
findings on the role of both opioids and NEP in cancer
development, authors agree that their role seems to depend
on the origin, stage and grade of tumor, and even on the
method of examination. Moreover, recently, natural
inhibitors of NEP, such as sialorphin, opiorphin and spin-
orphin have been detected. Their analgesic activity has
been established. It is interesting to ask whether there is a
relationship among opioid peptides, tumor-associated NEP
and its inhibitors.
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Abbreviations
AKT Protein kinase B/AKT
APN Aminopeptidase N
CALLA Common acute lymphoblastic leukemia
antigen
CC Colon cancer
CKI Cyclin dependent inhibitory kinases
ECM Extracellular matrix
FAK Focal adhesion kinase
GPI-complex Glycosyl phosphatidyl inositol complex
MAP kinases Mitogen-activated protein kinases
mRNA Messenger RNA
NEP Neutral endopeptidase
NK Natural killer cells
OGF Opioid growth factor
OGFr Opioid growth factor receptor
PROL1 Proline rich, lacrimal 1
PTEN Phosphatase and tensin homolog deleted
on chromosome Ten
SGP-T Submandibular gland peptide-T
SMR1 Submandibular rat1 protein
TGF-b1 Tumor growth factor b1
VCSA1 Variable coding sequence A1
Opioid Peptides and Cancer Cells
Opioids are a group of both naturally occurring and syn-
thetically produced molecules, traditionally known by their
analgesic activity.
Opium alkaloids derived from plants, for example,
morphine, are commonly used as medicines and are
regarded as the ‘‘gold standard’’ for relieving severe pain
associated with cancer (Lutz and Kieffer 2013). Moreover,
other than pain-suppressive activities of exogenous opioids
have been widely examined. It has been observed that
morphine exerts both tumor-growth promoting and growth
inhibiting activities, by influencing the proliferation and
migration of tumor cells and angiogenesis as well as by
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affecting the immune system (Gach et al. 2011; Harimaya
et al. 2002; Scha¨fer and Mousa 2009; Tabellini et al. 2014).
In animals, naturally occurring opioid peptides are
synthesized as prohormones. Most currently known
endogenous opioids originate from three types of prohor-
mones: proenkephalins, pro-opiomelanocortins and
prodynorphins (Hughes et al. 1975; Simon et al. 1973;
Terenius 1973). Despite their different activities in living
organisms, these endogenous peptides possess common
structural features, namely, an N-terminal enkephalin
sequence in molecules comprised of 5–40 amino acid
residues (Civelli and Douglass 1986; Thanawala et al.
2008). [Met5]-enkephalin and [Leu5]-enkephalin, the first
endogenous peptides discovered, differed only at the
C-terminal residues (Akil et al. 1984).
The Presence and Activity of Opioid Peptides
Many studies have indicated that opioid peptides possess-
ing an enkephalin sequence are widely spread in the human
body, where they play a broad variety of functions. Among
others, they act as neuromodulators and growth factors
through interaction with l, d and j opioid receptors
(McDonald and Lambert 2005; McLaughlin and Zagon
2012). Neuromodulatory activities of endogenous opioid
peptides are connected with inhibition of the release of
bioactive compounds, e.g., dopamine; regulation of pain
and motor activity; gastrointestinal motility and peristalsis;
regulation of emotional behavior; appetite and thirst and
many others (Bauvois and Dauzonne 2006; Bohlen and
Dermietzel 2006; McLaughlin and Zagon 2012).
The presence of opioid peptide receptors and/or their
agonists has been established not only in neurons but also
in immune cells (granulocytes, monocytes/macrophages,
lymphocytes, natural killer cells) (Iwaszkiewicz et al.
2013; Li et al. 2013; Scha¨fer and Mousa 2009) and tumor
cells originating from colon cancer (CC), breast cancer,
lung cancer, pancreatic cancer, thyroid cancer, endocrinal
tumors, endometrial carcinoma, glioma and melanoma
(Fichna and Janecka 2004).
Opioid Growth Factor
At the end of the twentieth century, Zagon and his team
proposed a hypothesis that opioid peptides also act as
growth regulators (McLaughlin and Zagon 2012). This was
related especially to [Met5]-enkephalin which was,
accordingly, renamed as the opioid growth factor (OGF)
(Zagon and McLaughlin 1987, 1988, 1989, 1991; Zagon
et al. 1987, 1997, 1999b). OGF is a non-cytotoxic molecule
produced in an autocrine and paracrine fashion. Extensive
research has demonstrated that OGF and its receptor,
OGFr, exert their activity through protein/RNA synthesis-
dependent regulation of cell proliferation (Bisignani et al.
1999; Donahue et al. 2009; Hatzoglou et al. 2005;
McLaughlin and Zagon 2012). Studies on normal and
cancer cells have revealed that OGF arrests the cell cycle at
phase G1/S through modulation or upregulation of cyclin-
dependent inhibitory kinases p16 and p21. This results in
the inhibition of DNA synthesis and subsequent arrest of
receptor-dependent proliferation of non-malignant and
cancer cells (Cheng et al. 2007, 2008, 2009; Donahue et al.
2009). The OGF and its receptor are engaged in the
maintenance of homeostasis through regulation of cell
proliferation, tissue (heart, corneal epithelium, astrocyte,
mesenchymal cell) development and renewal, as well as
wound healing and angiogenesis (Blebea et al. 2000;
Isayama et al. 1991; McLaughlin 1996; McLaughlin and
Zagon 2012; Zagon and McLaughlin 1987, 1988, 1991;
Zagon et al. 2000, 2002). The inhibitory activity of the
OGF-OGFr axis has also been assessed in vitro and in vivo
against cancer cells derived from neuroblastoma, pancre-
atic adenocarcinoma, colon adenocarcinoma, head and
neck squamous cell carcinoma, and renal, ovarian and
breast tumors (Donahue et al. 2009; Hatzoglou et al. 2005;
McLaughlin and Zagon 2012; McLaughlin et al. 1999a, b;
Zagon et al. 1999a, 2009). On the other hand, there are
some reports which indicate that opioid peptides (espe-
cially [Met5]-enkephalin) secreted by cancer cells, e.g.,
colon cancer, can suppress immune response to promote
cancer progression and invasiveness (Ohmori et al. 2009).
In the case of CC, a relationship has been found between
the expression level of the opioid peptide and tumor-infil-
trating T lymphocytes. In general, the number of
lymphocytes T, bearing the d opioid receptor, decreased
along with increased Met5-enkephalin expression (Ohmori
et al. 2009).
Enzymes Degrading [Met5/Leu5]-Enkephalin Type
Opioids
Opioid peptides are engaged in a wide range of processes,
presenting both advantages and disadvantages to living
organisms. Their characteristic feature is a short half-life
associated with the rapid degradation of those peptides by
endogenous enzymes (Janecka et al. 2008; Kreczko and
Mac´kiewicz 2011). Neutral endopeptidase (NEP, neprilysin,
enkephalinase, CD10, EC 3.4.24.11, common acute lym-
phoblastic leukemia antigen) and aminopeptidase N (APN,
CD13, EC 3.4.11.2) are two of the many enzymes involved in
the degradation of endogenous opioid peptides (Janecka
et al. 2008; Kreczko and Mac´kiewicz 2011; Schreiter et al.
2012). These enzymes are widely distributed in living
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organisms and engaged in diverse physiological and patho-
logical processes.
NEP and APN are membrane-bound, zinc-dependent
metallopeptidases of the gluzincin family. NEP gene is
located on human chromosome 3q21–27, whereas APN
gene on chromosome 15q25-26 (Maguer-Satta et al. 2011;
Noren et al. 1997). Both genes may be differentially
expressed, in a tissue-specific manner (Carl-McGrath et al.
2006; Maguer-Satta et al. 2011). The CD10 gene encodes a
90–110 kDa and CD13 gene an approximately 150 kDa
type II membrane protein (Carl-McGrath et al. 2006; Ma-
guer-Satta et al. 2011; Noren et al. 1997). NEP cleaves
peptide bonds on the amino side of hydrophobic residues
and has also peptidyl-dipeptidase activity with some sub-
strates (Rogues et al. 1993), whereas APN preferentially
cleaves N-terminal unsubstituted neutral amino acids from
proteins (Noren et al. 1997).
Implications of NEP and APN for Health and Disease
Neutral endopeptidase and APN are widely distributed
among different tissues and organs, where they play certain
roles.
Neutral Endopeptidase
In the central nervous system, NEP processes enkephalin,
an opioid peptide liberated by neurons in response to pain
and substance P (Rogues et al. 1993). NEP is known as an
amyloid b-peptide-degrading enzyme. Its dysfunction leads
to an accumulation of insoluble neurotoxic b amyloid
peptide and neuronal death in Alzheimer’s disease (Iwata
et al. 2001; Yasojima et al. 2001). Recently, it has been
demonstrated that the neuroprotective activity of kynurenic
acid is associated, at least partially, with the induction of
the expression and/or activity of NEP in nerve cells (Klein
et al. 2013). In the immune system, NEP is present on the
surface of neutrophils. It regulates the activation of
immunocompetent cells by degrading inflammatory pep-
tides such as endothelin, bradykinin, atriopeptin and
interleukin-1. It is known that NEP also processes
somatostatin, neurokinin, cholecystokinin-8, angiotensin-I
and-II, gastrin-related protein, calcitonin, calcitonin gene-
related peptide and bombesin. NEP (CD10) has been used
as a marker of stem cells in normal tissues. It is engaged in
tissue morphogenesis and cell differentiation, among others
in the lung and mammary gland. This enzyme is also
implicated in the maturation of B cells (Carl-McGrath et al.
2006; Maguer-Satta et al. 2011).
Many previous studies have indicated that CD10 plays
an important role in tumor progression (Carl-McGrath et al.
2006; Fujita et al. 2007). NEP (CD10) might be a very
useful tool in the diagnosis and prognosis of B-lineage
acute lymphoblastic leukemia and several carcinomas
originating from kidney, lung, skin, pancreas, prostate,
liver, breast, stomach, cervix and bladder. It has been
detected that NEP can be up- or down-regulated in neo-
plastic cells. Moreover, it should be underlined that the
expression level of NEP is dependent on the proliferation
and differentiation status of tumor cells. NEP is implicated
both indirectly and directly in the regulation of signaling
pathways mediating cell migration, proliferation and sur-
vival. This indirect action results from proteolytic
degradation or activation of bioactive peptides, growth
factors and cytokines, which creates a microenvironment
that facilitates tumor cell proliferation, invasion and
metastasis. In addition to its function mediated through
enzymatic activity, NEP regulates signaling pathways in a
direct fashion. It acts as an immune receptor anchored in
the cell membrane through GPI-complexes. CD10 is
implicated in cell migration, cell proliferation and survival
through focal adhesion kinase and PTEN/AKT signaling
pathways. These functions of NEP have been extensively
explored among others in prostate cancer, but not in CC
(Carl-McGrath et al. 2006; Maguer-Satta et al. 2011;
Sumitomo et al. 2000, 2001, 2004, 2005). The CD10
antisense S-oligodeoxynucleotide treatment of CD10-
positive CC cell line, HT-29 resulted in inhibition of
growth, invasion and colony formation (Luo et al. 2009).
Further studies indicated that NEP contributes to liver
metastasis of CC cells by degradation of the anti-tumoral
peptide, Met5-enkephalin (Kuniyasu et al. 2010; Luo et al.
2009).
Aminopeptidase N
The numerous studies on APN biological roles revealed
that APN is involved in both physiological and patholog-
ical processes including cancers and inflammatory
diseases. APN plays its functions through degradation of
diverse bioactive peptides, e.g. vasoactive peptides, neu-
ropeptides, chemotactic peptides and extracellular matrix
(ECM) (Bauvois and Dauzonne 2006; Carl-McGrath et al.
2006). Moreover, APN is implicated in cell signaling
pathways involving MAP kinases and Wnt-5a protoonco-
gen (Lendeckel et al. 1998, 2000).
It was widely investigated that APN is engaged in reg-
ulation of cell growth and maturation (Bauvois and
Dauzonne 2006). Similar to NEP, APN is considered as a
marker of differentiation as it is expressed on stem cells
and on leukocytes dependent on their stage of differentia-
tion (Razak and Newland 1992a, b). Moreover, it is
implicated in immune response mechanisms. APN is con-
sidered to regulate the secretion of proinflammatory and
immunosuppressive cytokines (Lendeckel et al. 2003;
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Mishima et al. 2002). The important role APN plays in
modulation of cell motility. It is executed not only by
chemokines processing but also the degradation of ECM
components. Taking into account the fact that many types
of malignant cancers overexpressed APN, this function of
peptidase seems to be especially important in tumor inva-
siveness and metastasis (Carl-McGrath et al. 2006; Fujii
et al. 1996; Hashida et al. 2002; Saiki et al. 1993). More-
over, the ability of APN to EMC degradation implicates it
in both physiological and pathological angiogenesis pro-
cesses (Aozuka et al. 2004; Bhagwat et al. 2001; Fukasawa
et al. 2006; Pasqualini et al. 2000; van Hensbergen et al.
2003). It was also demonstrated that APN acts as an
adhesion molecule during angiogenic morphogenesis
(Fukasawa et al. 2006).
Colon Cancer
The development and growth of tumor cells result from the
accumulation of mutations during carcinogenesis. These
mutations lead to essential alterations in cell physiology
that dictate malignant growth characterized by self-suffi-
ciency with respect to growth signals, insensitivity to
growth-inhibitory signals or sensitivity to weak growth
signals not detected by normal cells; resistance to cell
signals inducing death and elimination of defective cells;
limitless replicative potential; and the ability to induce
angiogenesis, evasion of the nearest tissues and metastasis
(Hanahan and Weinberg 2000). The promotion of prolif-
eration, inhibition of apoptosis, invasion and migration
through tissues as well as the induction of angiogenesis
during carcinogenesis are regulated by autocrine and par-
acrine growth factors, cytokines, hormones and signaling
peptides. The availability of these extracellular signaling
molecules is regulated through proteolysis, which may be
mediated among others by cell membrane-bound pepti-
dases, e.g. NEP and APN, expressed on the surface of
tumor, stromal and endothelial cells. These multifunctional
proteins are asymmetrically oriented in the cell membrane,
with the catalytic site exposed to the extracellular surface.
This enables them to release many growth factors and their
receptors into the circulation, remodel the ECM as well as
activate or inactivate the circulating signaling molecules
through proteolysis (Carl-McGrath et al. 2006).
Colon carcinoma is one of the most frequent tumors in the
world. The life expectancy in patients with the metastatic
form of this tumor has been extended in the past decade, but
the disease still remains incurable. The development of CC,
which starts with changes in normal colonic epithelium
through adenomatous polyps to metastatic cancer is depen-
dent on and supported by the tumor microenvironment. The
components of the tumor microenvironment include stroma
cells, vasculature, nerves and the ECM with associated
molecules. The essential part of stroma cells are tumor-
associated fibroblasts, which produce a set of factors facili-
tating tumor growth and promoting angiogenesis. They also
enable tumor invasion and metastasis, and produce ECM
components with associated molecules (Colucci et al. 2005,
2008; Mayordomo et al. 2012; Peddareddigari et al. 2010).
Additionally, transformed epithelial cells modulate the
function of their microenvironment to facilitate their own
growth, survival, invasion and metastasis (Peddareddigari
et al. 2010). One of the most important growth factors
expressed by both colon cancer tumor cells and tumor-
associated fibroblasts, which regulates cancer development,
is tumor growth factor (TGF)-b. In the case of CC, its
function depends on the tumor stage. In early stages, TGF-b1
acts as a tumor suppressor, whereas in later stages it presents
cancer-promoting activities (Paduch and Kandefer-Szerszen´
2009; Peddareddigari et al. 2010). TGF-b1 is secreted in a
latent complex, covalently linked to ECM, from which it is
released by proteases such as metalloproteases (McMahon
et al. 1996).
The Expression of NEP by CC Cells
The studies on NEP/CD10 in CC cells were concerned
mainly on comparisons of the protein level in tissue sam-
ples of colon adenocarcinoma with non-neoplastic adjacent
tissues, with respect to degrees of tumor differentiation,
invasion and metastasis. These reports, however, are dis-
crepant in some aspects. For example, de Oliveira et al.
(2011) and Sato et al. (1996) have reported that the level of
CD10 expression was higher in CC tissue samples than in
non-neoplastic mucosa adjacent to the tumor, whereas
Ogawa et al. (2002) have not found any expression of this
marker in samples of normal tissue. Sato et al. (1996) and
Fujimoto et al. (2005) have identified a higher expression
level of CD10 in well or/and moderately differentiated
adenocarcinoma tissue specimens in comparison with
poorly differentiated ones. On the other hand, de Oliveira
et al. (2011) and Oshima et al. (2007) have not observed
any difference in the expression regarding histological
differentiation. The lymphatic, vascular and/or perineural
invasion of colorectal carcinoma has been found to be
associated with CD10 expression by Fujimoto et al. (2005)
and Yao et al. (2002), whereas de Oliveira et al. (2011) and
Fujita et al. (2007) have not observed a significant rela-
tionship of this kind. Moreover, there are some
controversies regarding the expression level of CD10 and
metastasis. Fujimoto et al. (2005) and Yao et al. (2002)
have identified a strong expression of this marker in
patients with a higher incidence of liver metastases. On the
other hand, de Oliveira et al. (2011) and Fujita et al. (2007)
have not found any relationship between these two
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parameters. It should be underlined that Fujita et al. (2007)
studied the expression of CD10 on the mRNA level not the
CD10 protein level. It is possible that those discrepancies
are caused by the fact that those authors examined tumors
at different stages of development.
Inhibitors of Enkephalin-Degrading Enzymes
Rapid degradation of peptide opioids is especially unde-
sired when they exert a beneficial action, e.g., analgesic,
anti-inflammatory and antitumoral. This has prompted
scientists to search for natural or synthetic inhibitors of
enkephalin-degrading enzymes and endomorphin analogs
with an increased stability (Janecka et al. 2008; Kreczko
and Mac´kiewicz 2011; Rougeot et al. 2003; Schreiter et al.
2012; Wisner et al. 2006; Yamamoto et al. 2002).
Recently, three naturally occurring inhibitors of
enkephalin-degrading enzymes have been discovered: sia-
lorphin, opiorphin and spinorphin.
Sialorphin is an exocrine and endocrine signaling pen-
tapeptide (QHNPR), synthesized mainly in the
submandibular gland and prostate of adult rats in response
to androgen steroids. To our knowledge, the occurence of
this peptide was determined in milk and placenta, in
addition to saliva and urine (Dufour et al. 2013; Rougeot
2004). The sialorphin gene, VCSA1, encodes the precursor
prohormone, the submandibular rat1 protein (SMR1). It is
processed also into other bioactive peptides, namely hep-
tapeptide with the sequence TDIFEGG, named
submandibular gland peptide-T and its C-terminal deriva-
tive, tripeptide FEG. The last mentioned above peptides are
considered as regulators of inflammatory and allergic
reactions in various animal models (Mathison et al. 2010;
Morris et al. 2007). Sialorphin is released locally and
systematically from SMR1 protein. It is also acutely
secreted in response to stress (Rougeot et al. 2003). Rou-
geot et al. (2003) have provided evidence that sialorphin is
a natural inhibitor of the cell surface NEP in several
mammals models. This indicates the lack of species-spe-
cific activity, similar to TDIFEGG peptide (Morris et al.
2007). It has been demonstrated that this peptide acts as a
competitive inhibitor of renal and spinal NEP, inhibiting
the degradation of substance P and Met5-enkephalin and
thus displaying analgesic activity (Rougeot et al. 2003). It
has also been postulated that sialorphin could be involved
in the regulation of systemic mineral ion homeostasis due
to distribution of its peripheral target sites within tissues
engaged in the regulation of ion capture and transport
(Rougeot et al. 2003). Moreover, this inhibitor causes the
enhancement of sexual behaviour and increased erectile
function of male rats (Kos and Popik 2005; Messaoudi
et al. 2004).
Opiorphin is a human pentapeptide (QRFSR) which was
first discovered in saliva and characterized by an inhibitory
activity against two enkephalin-degrading enzymes, NEP
and APN (Wisner et al. 2006). Recently, the expression of
opiorphin was additionally identified in male reproductive
system, in mammary and lachrymal glands. This results in
the occurence of peptide in semen, milk, tears, human
plasma and even urine (Dufour et al. 2013). It is of interest
that the secretion and concentration pattern of opiorphin is
differentiated. It depends on gender and type of organ
(Dufour et al. 2013). It was determined that opiorphin
displays analgesic and antidepressant activity in in vivo
animal models of pain and depression (Javelot et al. 2010;
Popik et al. 2010; Rougeot et al. 2010; Tian et al. 2009;
Yang et al. 2011). It is worth to be underlined that opior-
phin is as effective as morphine on acute pain (Rougeot
et al. 2010). Moreover, it is well documented that opior-
phin demonstrated weaker or even no adverse side effects
e.g. addiction or tolerance at active doses used in in vivo
tests what is typical for morphine usage (Popik et al. 2010;
Rougeot et al. 2010). It is proved that opiorphin displays
these features by potentiating the activation l- and d-opioid
pathways. This is resulted from inhibition of NEP- and/or
APN-mediated degradation of endogenous enkephalins,
similarly as in case of sialorphin (Javelot et al. 2010;
Rougeot et al. 2003, 2010; Tian et al. 2009; Wisner et al.
2006).
Spinorphin, a bovine heptapeptide (LVVYPWT)
belonging to the hemorphin family has been isolated from
the spinal cord (Nishimura and Hazato 1993b). It presents
inhibitory activity against enkephalin-degrading enzymes
such as NEP, APN and dipeptidyl peptidase III (Nishimura
and Hazato 1993a). This feature of spinorphin is a pre-
requisite for its analgesic and anti-inflammatory activity
(Chen et al. 2000; Honda et al. 2001; Polosa et al. 1997;
Thanawala et al. 2008; Yamamoto et al. 1997, 2002). The
in vitro and in vivo studies indicated that this inhibitor acts
as antagonist of N-formylpeptide receptor subtype FPR
which resulted in blockage of fMet-Leu-Phe-induced
stimulation of neutrophils (Liang et al. 2001; Yamamoto
et al. 1997).
Conclusion
It is well documented that endogenous and exogenously
administered opioids are engaged in the regulation of stress
and inflammation, wound healing, elimination of pathogen
invasion and tumor growth. The findings regarding the
effects of the action of opioids, especially concerned tumor
development, are, however, contradictory. This issue has
been widely reviewed by Gach et al. (2011). Some studies
have pointed to the inhibitory action of endogenous opioid
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peptides on normal and tumor cell proliferation. Their
immunosuppressive action has been regarded as beneficial in
chronic inflammation. On the other hand, there are reports
indicating that this feature of opioids is detrimental to tissue
repair and tumor progression and metastasis. In spite of these
discrepancies, there is some interest among researchers, in
substances that inhibit the activity of enzymes degrading
opioid peptides, among other NEP. The use of such inhibitors
would allow to replace the administration of detrimental
exogenous opioids, e.g., morphine, in patients with tumors.
Although the role of NEP in tumor biology is well estab-
lished, there are still no data on the inhibition of tumor-
associated NEP by naturally occurring inhibitors, e.g., sia-
lorphin, opiorphin, spinorphin or their derivatives. It is,
therefore, interesting and worthwhile to examine whether
natural inhibitors and their synthetic derivatives could
modulate the activities of cancer cells expressing NEP such
as, for example, colon cancer cells. The natural inhibitors of
NEP are peptide molecules easily degraded by endogenous
proteases. Numerous studies are carried out to increase
their stability and bioactive availability or to improve their
biological activity in relation to amino acid sequence and
molecule structure (Bogeas et al. 2013; Jung et al. 2007;
Kamysz et al. 2013a, b; Kotynia et al. 2010; Rosa et al.
2012). This may be advantageous to relieve the pain con-
nected with cancer development or treatment and
simultaneously to abrogate or diminish the development of
pathological processes. It seems that the study of the opioid
peptides-neutral endopeptidase-NEP inhibitors axis could
be a step towards achieving this goal.VCSA1 gene encoding
the precursor of rat sialorphin and the PROL1 gene
encoding human opiorphin are members of the same gene
family identified in rat, mouse and human. It was proved
that the products of these genes do not present species
specificity considering the interactions with target. It has
also been found that the target of sialorphin, opiorphin and
bovine spinorphin, namely NEP, is highly conserved
among different mammalian species (C93 % sequence
homology in rat and human) (Rougeot et al. 2003; Wisner
et al. 2006). Taking into account the considerations above,
these peptide inhibitors constitute potentially therapeutic
inhibitors of NEP.
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